116 results
8-K
EX-99.1
LADX
LadRx Corp
26 Jun 23
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
6:20am
the proceeds primarily to advance its lead novel cancer therapeutic candidate LADR-7 towards an Investigation New Drug filing (“IND”) with the FDA
8-K
EX-10.1
LADX
LadRx Corp
26 Jun 23
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
6:20am
) the consummation by the Seller of any of the transactions contemplated by this Agreement.
Section 4.6 No Litigation. There is no action, suit, investigation … is not in violation of, and to the Knowledge of the Seller, the Seller is not under investigation with respect to nor has the Seller been threatened
8-K
EX-10.2
LADX
LadRx Corp
26 Jun 23
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
6:20am
contemplated by this Agreement.
(f) No Litigation. There is no action, suit, investigation or proceeding pending before any Governmental Entity … of Assignor, Assignor is not under investigation with respect to nor has the Assignor been threatened to be charged with or given notice of any violation
8-K
EX-10.2
sw7wq8
4 Jan 22
CytRx Announces the Appointment of Dr. Stephen
9:09am
8-K
EX-10.1
epfy5v5ogrmq7
4 Jan 22
CytRx Announces the Appointment of Dr. Stephen
9:09am
8-K
EX-10.1
fxjnm7f4
15 Jul 21
Entry into a Material Definitive Agreement
8:55am
8-K
EX-10.2
x8sihjxeo0
15 Jul 21
Entry into a Material Definitive Agreement
8:55am
8-K
EX-3.1
sb3fd0wq hfgcdrb
15 Jul 21
Entry into a Material Definitive Agreement
8:55am
8-K
EX-10.1
gqiacqvdtg 5t2
16 May 18
CytRx Announces $7.0 Million Registered Direct Offering
12:00am
8-K
EX-10.2
zf1vqp0
16 May 18
CytRx Announces $7.0 Million Registered Direct Offering
12:00am